Christine Akinc

Bio:

Christine Lindenboom joined Alnylam in 2015 as Vice President, Investor Relations & Corporate Communications, was promoted to Senior Vice President, Investor Relations & Corporate Communications in 2019, and was promoted to Chief Corporate Communications Officer in 2024. Christine leads a multidisciplinary team responsible for external & internal communications, corporate responsibility, brand and creative and investor relations. During her time at Alnylam, she has helped scale the company globally, launched 5 products in 4 years, and contributed to building its award-winning culture.

Before joining Alnylam, Christine served as Senior Director, Corporate Communications at Pfizer where she supported internal and external communications for R&D, and also served in various roles in media relations. Before her time at Pfizer, she led corporate media relations for Amgen, supporting executive, tax, litigation, finance and M&A. In her prior role at Amgen, she led communications for the oncology therapeutics franchise and led launch communications for XGEVA and VECTIBIX. Prior to joining Amgen, she worked at FleishmanHillard, a public relations firm, supporting various pharmaceutical and biotech clients, and she started her career in the communications group of Millennium Pharmaceuticals, where she helped launch VELCADE.

Christine is a member of the Board of Directors of Invivyd, Inc., a clinical-stage biopharmaceutical company. She received a Bachelor of Arts from Northeastern University.